In addition to the financial highlights, Biofrontera provided updates on its operational achievements, including positive results from its Phase 2b clinical trial for Ameluz in treating moderate to severe acne vulgaris and the FDA's acceptance of its supplemental New Drug Application for Ameluz Photodynamic Therapy for superficial basal cell carcinoma. The company also announced the completion of its strategic transaction with Biofrontera AG, which has strengthened its cost profile and operational capabilities. CEO Hermann Luebbert emphasized that 2025 was a transformational year for the company, with expectations for sustained profitability and cash flow breakeven in 2026. The company will hold a conference call today at 10:00 AM ET to discuss these results further.
2026-03-19 13:37:09
Biofrontera Inc. Reports Record Q4 2025 Financial Results with 36% Revenue Growth
Expected Stock impact: Noticeably Positive
On March 19, 2026, Biofrontera Inc. (NASDAQ: BFRI) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported record revenues of $17.1 million for Q4 2025, representing a 36% increase compared to $12.6 million in the same period of 2024. This growth was primarily driven by strong sales execution of its Ameluz product and a pricing adjustment implemented in December 2025. The gross profit margin for the fourth quarter was reported at 82.4%, a significant increase from 58.0% in Q4 2024, reflecting the transition away from the previous transfer pricing model under the prior license agreement. Operating income for the quarter was $4.6 million, a notable turnaround from a loss of $1.7 million in Q4 2024. The company ended the year with a cash balance of $6.4 million as of December 31, 2025.
In addition to the financial highlights, Biofrontera provided updates on its operational achievements, including positive results from its Phase 2b clinical trial for Ameluz in treating moderate to severe acne vulgaris and the FDA's acceptance of its supplemental New Drug Application for Ameluz Photodynamic Therapy for superficial basal cell carcinoma. The company also announced the completion of its strategic transaction with Biofrontera AG, which has strengthened its cost profile and operational capabilities. CEO Hermann Luebbert emphasized that 2025 was a transformational year for the company, with expectations for sustained profitability and cash flow breakeven in 2026. The company will hold a conference call today at 10:00 AM ET to discuss these results further.
In addition to the financial highlights, Biofrontera provided updates on its operational achievements, including positive results from its Phase 2b clinical trial for Ameluz in treating moderate to severe acne vulgaris and the FDA's acceptance of its supplemental New Drug Application for Ameluz Photodynamic Therapy for superficial basal cell carcinoma. The company also announced the completion of its strategic transaction with Biofrontera AG, which has strengthened its cost profile and operational capabilities. CEO Hermann Luebbert emphasized that 2025 was a transformational year for the company, with expectations for sustained profitability and cash flow breakeven in 2026. The company will hold a conference call today at 10:00 AM ET to discuss these results further.
